A PILOT-STUDY OF CLONIDINE PLUS PHYSOSTIGMINE IN ALZHEIMERS-DISEASE
A PILOT-STUDY OF CLONIDINE PLUS PHYSOSTIGMINE IN ALZHEIMERS-DISEASE
复制标题
DOI：
10.1159/000106731
复制
发表时间：
1994-09-01
期刊：
影响因子：
--
通讯作者：
DAVIS, KL
中科院分区：
文献类型：
--
作者：
BIERER, LM;AISEN, PS;DAVIS, KL
为了评估一种联合胆碱能/去甲肾上腺素能治疗阿尔茨海默病的方法的可行性，10名患者参加了一项为期2周的安慰剂对照研究。采用阿尔茨海默病评估量表（ADAS）作为主要结局指标。无论是单独使用毒豆豉碱，还是联合使用毒豆豉碱加可乐定，都与该组的统计学显著改善无关。三名患者在药物联合治疗后ADAS总分至少提高了4分。讨论了这些结果对治疗策略的影响。
To assess the feasibility of one approach to combined cholinergic/noradrenergic treatment in Alzheimer's disease, ten patients were enrolled in a 2-week placebo-controlled study of oral physostigmine plus clonidine. The Alzheimer's Disease Assessment Scale (ADAS) was used as the primary outcome measure. Neither physostigmine alone, nor the combination of physostigmine plus clonidine, was associated with a statistically significant improvement for the group. Three patients did show an improvement of at least 4 points on the total ADAS score with the drug combination. The implications of these results for treatment strategies are discussed.